EEG@HOME (Phase 3b of the Project, Interviews)

Epilepsy Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02428348
• Other study ID #: EC/2014/1283(2)
• Status: Terminated
• Phase: N/A
• First received: March 31, 2015
• Last updated: November 27, 2017
• Start date: January 2015
• Est. completion date: October 2015

Study information

• Verified date: November 2017
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this project is the development of an EEG-cap (min. 21 electrodes) with user-friendly active dry electrodes that meets the expectations of the users regarding comfort and esthetics, without losing sight of the functional and technical demands for recording high quality EEG signals. The purpose is to use the EEG-cap to investigate clinical neurological disorders (e.g. epilepsy). The EEG-cap could also be used at home so that hospital admission in the EMU can be avoided for some patients and an increasing number of patients can be examined.

Phase 3 of this Project will be divided into Phase 3a and Phase 3b.

In Phase 3b of the project epilepsy patients and their family will be interviewed about different EEG-cap models in development. This interview is anticipated to take approximately 1 hour.

Minimum 4 - maximum 20 epilepsy patients and their family will be interviewed.

The results of the interviews will be analysed by the design company pilipili nv.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: October 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 80 Years

Eligibility

Inclusion Criteria:

• Epilepsy patient

Exclusion Criteria:

• No experience with EEG

Related Conditions & MeSH terms

• Epilepsy

Intervention

Other:
• Interview about prototype EEG-cap

Locations

Country	Name	City	State
Belgium	University Hospital Ghent	Ghent

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Ghent	Imec, Pilipili NV

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	User opinion (questionnaire)		1 hour